Wilhelmus Egbertus Arnout de Witte
Research Subjects
Wilhelmus Egbertus Arnout de Witte has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Cunera Maria de Lange
Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research Leiden University Leiden The Netherlands
8 shared publications - Laura H. Heitman
Leiden University
3 shared publications Meindert Danhof
Department of Pharmacology, Leiden Academic Centre for Drug Research, Leiden, Netherlands
3 shared publications- Stephan Schaller
esqLABS GmbH Saterland Germany
3 shared publications - Alexander Kulesza
esqLABS GmbH Saterland Germany
2 shared publications - C. Andrew Boswell
Genentech, Inc., South San Francisco, CA 94080, USA
2 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 12
Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500
- 22 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 12
Open AccessCorrection: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500
- Open Access
- 9 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 500
Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
Background: T-cell-engaging bispecific (TCB) antibodies represent a promising therapy that utilizes T-cells to eliminate cancer cells independently of the major histocompatibility complex. Despite their success in hematologic cancers, challenges such as cytokine release syndrome (CRS), off-tumor toxicity, and resistance limit their efficacy in solid tumors. Optimizing biodistribution is key to overcoming these challenges. Methods: A physiologically based pharmacokinetic (PBPK) model was developed that incorporates T-cell transmigration, retention, receptor binding, receptor turnover, and cellular engagement. Preclinical biodistribution data were modeled using two TCB formats: one lacking tumor target binding and another with target arm binding, each with varying CD3 affinities in a transgenic tumor-bearing mouse model. Results: The PBPK model successfully described the distribution of activated T-cells and various TCB formats. It accurately predicted preclinical biodistribution patterns, demonstrating that higher CD3 affinity leads to faster clearance from the blood and increased accumulation in T-cell-rich organs, often reducing tumor exposure. Simulations of HER2-CD3 TCB doses (0.1 µg to 100 mg) revealed monotonic increases in synapse AUC within the tumor. A bell-shaped dose-Cmax relationship for synapse formation was observed, and Tmax was delayed at higher doses. Blood PK was a reasonable surrogate for tumor synapse at low doses but less predictive at higher doses. Conclusions: We developed a whole-body PBPK model to simulate the biodistribution of T-cells and TCB molecules. The insights from this model provide a comprehensive understanding of the factors affecting PK, synapse formation, and TCB activity, aiding in dose optimization and the design of effective therapeutic strategies.
- 9 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 500
Open AccessWhole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
Background: T-cell-engaging bispecific (TCB) antibodies represent a promising therapy that utilizes T-cells to eliminate cancer cells independently of the major histocompatibility complex. Despite their success in hematologic cancers, challenges such as cytokine release syndrome (CRS), off-tumor toxicity, and resistance limit their efficacy in solid tumors. Optimizing biodistribution is key to overcoming these challenges. Methods: A physiologically based pharmacokinetic (PBPK) model was developed that incorporates T-cell transmigration, retention, receptor binding, receptor turnover, and cellular engagement. Preclinical biodistribution data were modeled using two TCB formats: one lacking tumor target binding and another with target arm binding, each with varying CD3 affinities in a transgenic tumor-bearing mouse model. Results: The PBPK model successfully described the distribution of activated T-cells and various TCB formats. It accurately predicted preclinical biodistribution patterns, demonstrating that higher CD3 affinity leads to faster clearance from the blood and increased accumulation in T-cell-rich organs, often reducing tumor exposure. Simulations of HER2-CD3 TCB doses (0.1 µg to 100 mg) revealed monotonic increases in synapse AUC within the tumor. A bell-shaped dose-Cmax relationship for synapse formation was observed, and Tmax was delayed at higher doses. Blood PK was a reasonable surrogate for tumor synapse at low doses but less predictive at higher doses. Conclusions: We developed a whole-body PBPK model to simulate the biodistribution of T-cells and TCB molecules. The insights from this model provide a comprehensive understanding of the factors affecting PK, synapse formation, and TCB activity, aiding in dose optimization and the design of effective therapeutic strategies.
- Open Access
- 12 November 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (12) , 2068-2086
Local depletion of large molecule drugs due to target binding in tissue interstitial space
Drug–target binding determines a drug's pharmacodynamics but can also have a profound impact on a drug's pharmacokinetics, known as target‐mediated drug disposition (TMDD). TMDD models describe the influence of drug–target binding and target turnover on unbound drug concentrations and are frequently used for biologics and drugs with nonlinear plasma pharmacokinetics. For drug targets expressed in tissues, the effect of TMDD may not be detected when analyzing plasma concentration curves, but it might still affect tissue concentrations and occupancy. This review aimed to investigate the likeliness of such a scenario by reviewing the literature for a typical range of TMDD parameter values and their impact on local drug concentrations and target occupancy in a whole‐body PBPK model with TMDD. Our analysis demonstrated that tissue drug concentrations are impacted and significantly depleted in many physiological scenarios. In contrast, the effect on plasma concentrations is much lower, specifically for smaller organs with lower perfusion. Moreover, in scenarios with fast internalization of the drug–target complex, the distribution of large molecules from plasma to tissue interstitial space emerges as a rate‐limiting step for the drug–target interaction. These factors may lead to overpredicting local drug concentrations when considering only plasma pharmacokinetics. A sensitivity analysis revealed the high and not always intuitive impact of drug‐specific parameters, including the drug molecule hydrodynamic radius, dissociation constant (Kd), drug–target complex internalization rate constant (kint), and target dissociation rate constant (koff), on the drug's pharmacokinetics. Our analysis demonstrated that tissue TMDD needs to be considered even if plasma pharmacokinetics are linear.
- 12 November 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (12) , 2068-2086
Open AccessLocal depletion of large molecule drugs due to target binding in tissue interstitial space
Drug–target binding determines a drug's pharmacodynamics but can also have a profound impact on a drug's pharmacokinetics, known as target‐mediated drug disposition (TMDD). TMDD models describe the influence of drug–target binding and target turnover on unbound drug concentrations and are frequently used for biologics and drugs with nonlinear plasma pharmacokinetics. For drug targets expressed in tissues, the effect of TMDD may not be detected when analyzing plasma concentration curves, but it might still affect tissue concentrations and occupancy. This review aimed to investigate the likeliness of such a scenario by reviewing the literature for a typical range of TMDD parameter values and their impact on local drug concentrations and target occupancy in a whole‐body PBPK model with TMDD. Our analysis demonstrated that tissue drug concentrations are impacted and significantly depleted in many physiological scenarios. In contrast, the effect on plasma concentrations is much lower, specifically for smaller organs with lower perfusion. Moreover, in scenarios with fast internalization of the drug–target complex, the distribution of large molecules from plasma to tissue interstitial space emerges as a rate‐limiting step for the drug–target interaction. These factors may lead to overpredicting local drug concentrations when considering only plasma pharmacokinetics. A sensitivity analysis revealed the high and not always intuitive impact of drug‐specific parameters, including the drug molecule hydrodynamic radius, dissociation constant (Kd), drug–target complex internalization rate constant (kint), and target dissociation rate constant (koff), on the drug's pharmacokinetics. Our analysis demonstrated that tissue TMDD needs to be considered even if plasma pharmacokinetics are linear.
- 6 March 2023
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 50 (3) , 229-241
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules
Monoclonal antibodies, endogenous IgG, and serum albumin bind to FcRn in the endosome for salvaging and recycling after pinocytotic uptake, which prolongs their half-life. This mechanism has been broadly recognized and is incorporated in currently available PBPK models. Newer types of large molecules have been designed and developed, which also bind to FcRn in the plasma space for various mechanistic reasons. To incorporate FcRn binding affinity in PBPK models, binding in the plasma space and subsequent internalisation into the endosome needs to be explicitly represented. This study investigates the large molecules model in PK-Sim® and its applicability to molecules with FcRn binding affinity in plasma. With this purpose, simulations of biologicals with and without plasma binding to FcRn were performed with the large molecule model in PK-Sim®. Subsequently, this model was extended to ensure a more mechanistic description of the internalisation of FcRn and the FcRn-drug complexes. Finally, the newly developed model was used in simulations to explore the sensitivity for FcRn binding in the plasma space, and it was fitted to an in vivo dataset of wild-type IgG and FcRn inhibitor plasma concentrations in Tg32 mice. The extended model demonstrated a strongly increased sensitivity of the terminal half-life towards the plasma FcRn binding affinity and could successfully fit the in vivo dataset in Tg32 mice with meaningful parameter estimates.
- 6 March 2023
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 50 (3) , 229-241
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules
Monoclonal antibodies, endogenous IgG, and serum albumin bind to FcRn in the endosome for salvaging and recycling after pinocytotic uptake, which prolongs their half-life. This mechanism has been broadly recognized and is incorporated in currently available PBPK models. Newer types of large molecules have been designed and developed, which also bind to FcRn in the plasma space for various mechanistic reasons. To incorporate FcRn binding affinity in PBPK models, binding in the plasma space and subsequent internalisation into the endosome needs to be explicitly represented. This study investigates the large molecules model in PK-Sim® and its applicability to molecules with FcRn binding affinity in plasma. With this purpose, simulations of biologicals with and without plasma binding to FcRn were performed with the large molecule model in PK-Sim®. Subsequently, this model was extended to ensure a more mechanistic description of the internalisation of FcRn and the FcRn-drug complexes. Finally, the newly developed model was used in simulations to explore the sensitivity for FcRn binding in the plasma space, and it was fitted to an in vivo dataset of wild-type IgG and FcRn inhibitor plasma concentrations in Tg32 mice. The extended model demonstrated a strongly increased sensitivity of the terminal half-life towards the plasma FcRn binding affinity and could successfully fit the in vivo dataset in Tg32 mice with meaningful parameter estimates.
- Open Access
- 26 July 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (21) , 4121-4136
In vitroandin silicoanalysis of the effects ofD2receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations
Background and Purpose: Target binding kinetics influence the time course of the drug effect (pharmacodynamics) both (i) directly, by affecting the time course of target occupancy, driven by the pharmacokinetics of the drug, competition with endogenous ligands and target turnover, and (ii) indirectly, by affecting signal transduction and homeostatic feedback. For dopamine D2receptor antagonists, it has been hypothesized that fast receptor binding kinetics cause fewer side effects, because part of the dynamics of the dopaminergic system is preserved by displacement of these antagonists.Experimental Approach: Target binding kinetics of D2receptor antagonists and signal transduction after dopamine and D2receptor antagonist exposure were measuredin vitro. These data were integrated by mechanistic modelling, taking into account competitive binding of endogenous dopamine and the antagonist, the turnover of the second messenger cAMP and negative feedback by PDE turnover.Key Results: The proposed signal transduction model successfully described the cellular cAMP response for 17 D2receptor antagonists with widely different binding kinetics. Simulation of the response to fluctuating dopamine concentrations revealed that a significant effect of the target binding kinetics on the dynamics of the signalling only occurs at endogenous dopamine concentration fluctuations with frequencies below 1 min−1.Conclusions and Implications: Signal transduction and feedback are important determinants of the time course of drug effects. The effect of the D2receptor antagonist dissociation rate constant (koff) is limited to the maximal rate of fluctuations in dopamine signalling as determined by the dopamine koffand the cAMP turnover.
- 26 July 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (21) , 4121-4136
Open AccessIn vitroandin silicoanalysis of the effects ofD2receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations
Background and Purpose: Target binding kinetics influence the time course of the drug effect (pharmacodynamics) both (i) directly, by affecting the time course of target occupancy, driven by the pharmacokinetics of the drug, competition with endogenous ligands and target turnover, and (ii) indirectly, by affecting signal transduction and homeostatic feedback. For dopamine D2receptor antagonists, it has been hypothesized that fast receptor binding kinetics cause fewer side effects, because part of the dynamics of the dopaminergic system is preserved by displacement of these antagonists.Experimental Approach: Target binding kinetics of D2receptor antagonists and signal transduction after dopamine and D2receptor antagonist exposure were measuredin vitro. These data were integrated by mechanistic modelling, taking into account competitive binding of endogenous dopamine and the antagonist, the turnover of the second messenger cAMP and negative feedback by PDE turnover.Key Results: The proposed signal transduction model successfully described the cellular cAMP response for 17 D2receptor antagonists with widely different binding kinetics. Simulation of the response to fluctuating dopamine concentrations revealed that a significant effect of the target binding kinetics on the dynamics of the signalling only occurs at endogenous dopamine concentration fluctuations with frequencies below 1 min−1.Conclusions and Implications: Signal transduction and feedback are important determinants of the time course of drug effects. The effect of the D2receptor antagonist dissociation rate constant (koff) is limited to the maximal rate of fluctuations in dopamine signalling as determined by the dopamine koffand the cAMP turnover.
- Open Access
- 4 December 2017
- Published by Springer Nature in The AAPS Journal
- Vol. 20 (1) , 11
Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling
Selectivity is an important attribute of effective and safe drugs, and prediction of in vivotarget and tissue selectivity would likely improve drug development success rates. However, a lack of...
- 4 December 2017
- Published by Springer Nature in The AAPS Journal
- Vol. 20 (1) , 11
Open AccessTarget and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling
Selectivity is an important attribute of effective and safe drugs, and prediction of in vivotarget and tissue selectivity would likely improve drug development success rates. However, a lack of...
- Open Access
- 1 November 2017
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 109, S83-S89
The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation
- 1 November 2017
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 109, S83-S89
Open AccessThe influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation
- Top Cited Papers
- 1 June 2017
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (6) , 896-911
Kinetics for Drug Discovery: an industry-driven effort to target drug residence time
- 1 June 2017
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (6) , 896-911
Top Cited PapersKinetics for Drug Discovery: an industry-driven effort to target drug residence time
- Open Access
- 3 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 52
A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy
CC Chemokine Receptor 2 (CCR2) and its endogenous ligand CCL2 are involved in a number of diseases, including atherosclerosis. Several CCR2 antagonists have been developed as potential therapeutic agents, however theirin vivoclinical efficacy was limited. In this report, we aimed to determine whether 15a, an antagonist with a long residence time on the human CCR2, is effective in inhibiting the development of atherosclerosis in a mouse disease model. First, radioligand binding assays were performed to determine affinity and binding kinetics of 15a on murine CCR2. To assess thein vivoefficacy, western-type diet fed apoE−/−mice were treated daily with 15a or vehicle as control. Treatment with 15a reduced the amount of circulating CCR2+monocytes and the size of the atherosclerotic plaques in both the carotid artery and the aortic root. We then showed that the long pharmacokinetic half-life of 15a combined with the high drug concentrations ensured prolonged CCR2 occupancy. These data render 15a a promising compound for drug development and confirms high receptor occupancy as a key parameter when targeting chemokine receptors.
- 3 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 52
Open AccessA novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy
CC Chemokine Receptor 2 (CCR2) and its endogenous ligand CCL2 are involved in a number of diseases, including atherosclerosis. Several CCR2 antagonists have been developed as potential therapeutic agents, however theirin vivoclinical efficacy was limited. In this report, we aimed to determine whether 15a, an antagonist with a long residence time on the human CCR2, is effective in inhibiting the development of atherosclerosis in a mouse disease model. First, radioligand binding assays were performed to determine affinity and binding kinetics of 15a on murine CCR2. To assess thein vivoefficacy, western-type diet fed apoE−/−mice were treated daily with 15a or vehicle as control. Treatment with 15a reduced the amount of circulating CCR2+monocytes and the size of the atherosclerotic plaques in both the carotid artery and the aortic root. We then showed that the long pharmacokinetic half-life of 15a combined with the high drug concentrations ensured prolonged CCR2 occupancy. These data render 15a a promising compound for drug development and confirms high receptor occupancy as a key parameter when targeting chemokine receptors.
- 1 October 2016
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 37 (10) , 831-842
In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant
- 1 October 2016
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 37 (10) , 831-842
In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant